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Xiaojin Wu, Ying Wang, Yang Xu, Depei Wu, Aining Sun, Ziling Zhu, Yue Han, Huiying Qiu,
Xiaowen Tang, Zhengzheng Fu, Guangsheng He, Caixia Li, Xiao Ma, Yuejun LiuCytomegalovirus (CMV) can be classified into 4 subgroups based on genotype variation of the glycoprotein B
(gB) encoded by UL55 gene. Little is known about the CMV gB genotype distribution and its clinical implica-
tion in patients who receive hematopoietic stem cell transplant (HSCT) in China. In this study, which com-
prises 101 HSCT patients with CMV infection, we have found that 36 patients (35.64%) were infected with
CMV genotype gB1, 3 patients (2.97%) with gB2, 39 patients (38.61%) with gB3, 1 patient (0.99%) with gB4,
and 17 patients (16.83%) were infected with mixed CMV genotypes. We also found that CMV gB3 was
associated with a high risk of CMV pneumonitis; nevertheless, there were no significant differences among
patients with gB genotypes with respect to the other CMV diseases; no significant differences between
patients with gB genotypes with respect to type II-IV acute graft-verses-host disease (aGVHD) and chronic
GVHD (cGVHD) was found either. Interestingly, 5 patients (4.95%) were infected with a CMV variant that
lacked a signature RsaI digestion site determined by Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP), subsequent cloning and sequencing identified this CMV RsaI minus variant to be
novel, herein designated as gB5. Overall, these findings suggest that CMV gB1 and gB3 are prevalent among
HSCTrecipients with CMV infections, and gB3 CMV infection is a risky indicator for CMV pneumonitis; fur-
thermore, a novel CMV variant in a subset of Chinese HSCT recipients is identified and designated as gB5.
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Complications caused by infection remain an
important contributing factor of morbidity following
allogeneic hematopoietic stem cell transplantation
(HSCT) [1]. Cytomegalovirus (CMV) is currently
a significant pathogen in HSCT patients [2,3], and
CMV disease may manifest as fever, leukopenia,
thrombocytopenia, hepatitis, pneumonitis, andmyelo-
suppression [2,4]. It was reported that the existence ofDepartment of Hematology, the First Affiliated Hospital
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6/j.bbmt.2009.12.001CMV variants played an important role in the patho-
genesis of diseases, as these variants affected several
genes that might be responsible for the different
diseases related to CMV infection [5-8].
CMV glycoprotein B (gB) accounts for .50% of
the protein mass of the CMV envelope [9], which is
encoded by the UL55 gene. There are 4 major gB
genotypes, determined by the variations found in the
region surrounding the protease cleavage site [3].
Rare genotype has once been described in an AIDS
patient [10]. CMV gB genotype might be an important
determinant of viral virulence, and likely plays a role in
viral penetration into cells, and transmission of virus
among cells [6,11].
CMV gB3 and gB4 were reported to be associated
with death because of myelosuppression in HSCT pa-
tients [12], gB1was found to be associatedwith invasive
disease in solid organ transplant patients [13], gB2 was
associated with retinitis in AIDS patients [14,15], and
mixed genotypes was reported to be associated with
severe clinical manifestations in immunocompromised
patients [16]. However, most studies have failed to
demonstrate an association of gB genotypes with
CMV disease [17-19].647
Table 1. Patient Characteristics
Characteristics Number
Recipients 101
Median age (years) 29 (range 13-62)
Sex: male/female 58/43
Median follow-up time (months) 7 (range 460)
Positive cytomegalovirus serology
Donor+/Recipent + 91
Donor2/Recipent + 5
ABO blood type major incompatibility 58
Diagnosis
AML 19
ALL 23
CML 25
SAA 5
Others malignant disorders 29
Donor type
Autologous stem cell 5
Matched-sibling stem cell 65
Mistmatched related stem cell 10
Unrelated stem cell 21
GVHD prophylaxis
CsA 12
CsA + MTX 53
CsA + MTX + MMF + ATG 31
Conditioning
TBI/Cy 25
Bu/Cy 57
Flu/Bu 15
BEAM 4
Cell dose
Median CD34+ cell 106/kg 4.1 (1.9-18.8)
Median nucleated cell 108/kg 18.6 (9.7-50.3)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; SAA, severe aplastic
anemia; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan;
Flu, Fludarabine; GVHD, graft-versus-host disease; CsA, cyclosporine;
MMF, mycophenolate mofetil ATG, antithymocyte immunoglobulin;
MTX, methotrexate.
Figure 1. Genotypes recognized with PCR-RFLP. The PCR products
from recipients of HSCTwith CMV infections were digested with Hinf
I and RsaI, respectively, and then resolved on 3% agarose gels. The infor-
mative banding patterns were used to classify the genotypes of CMV.
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CMV gB genotype distribution and its correlation
with major complications including CMV disease
and graft-versus-host disease (GVHD) in HSCT pa-
tients. In this study, we determined the CMV gB geno-
types in 101 patients following HSCT at the First
Affiliated Hospital of Soochow University in China
and examined their correlation with clinical outcomes.MATERIALS AND METHODS
Clinical Samples and Patients
A group of patients receiving HSCT through 2004
to 2009 at the First Affiliated Hospital of Soochow
University for hematologicmalignancy were recruited,
and peripheral blood (PB) samples from those patients
with CMV infection (totally 101) were used for this
study. All patients and donors provided written in-
formed consent for the protocol, which was approved
by the hospital’s Ethics Committee. Patient character-
istics are summarized in Table 1. CMV disease was de-
fined by a compatible clinical examination associatedwith direct tissue culture or histologic evidence of
CMV disease in the absence of other etiology for the
clinical symptoms [2,4]. CMV viral syndrome was de-
fined as fever, leukopenia, and thrombocytopenia, to-
gether with the detection of CMVpp65 in blood with
antigenemia assay.
CMV Serodiagnostic and CMV pp65
Antigenemia Assay
Serum samples from all patients and donors were
assessed for anti-CMV IgG, IgM antibodies by ELISA
(CMV Quantization Kit, GenWay Biotech, Inc., San
Digeo, CA, USA). CMVpp65 was detected and quanti-
fied by indirect immunofluorescence of isolated PB
leukocytes obtained from EDTA-anticoagulated PB.
(HCMVpp65 kit indirect immunofluorescence, Tianjin
Super Biotechnology Development Co. Ltd, China).
CMV gB Genotyping with Polymerase Chain
Reaction-Restriction Fragment Length
Polymorphism (PCR-RFLP) and Sequence
Analyses
CMV gB genotyping was determined with the
methods described elsewhere [12]. In brief, DNA
extracted from 200 mL whole PB with the DNA blood
and tissue extraction kit (Qiagen, Chatsworth, CA,
USA) was used as template. A double PCR-RFLP
method was used to determine the genotyping. The
first round PCR was performed using primers
gB1292 and gB 1676; its product was used as a template
in the second round of amplification with primers
gB1292 and gB1613. All the PCR reaction was per-
formed in a total volume of 50 mL reaction mixture
containing 1 PCR buffer (10 mM Tris-HCl, 20
mM MgSO4,10 mM KCl, 8 mM (NH4)SO4), 200
Figure 2. Sequence comparison.
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and 50 ng genomic DNA. The second round PCR
products were digested with HinfI and RsaI, respec-
tively, and then separated on 3% agarose gel. The
informative banding patterns were indicatives of each
genotype (Figure 1).
To determine the sequences of the HCMV gB
genotype samples, the PCR products were purified
with the PCR purification kit (Qiagen), and sub-
cloned into the pGEM-T vector (Promega, Madison,
WI, USA). The sequences were obtained with the
ABI 310 Genetic Analyser (Applied Biosystems, Bed-
ford, MA, USA) with proper primers, and they were
aligned with known CMV variants in GenBank
afterward.Statistical Analysis
Statistical analyses were performed with SAS 8.0
software package. A chi-square test was used to com-
pare the proportion of patients who experienced this
complication across gB types and multivariate propor-
tional hazard regression models were used to identify
independent risk factors of CMV pneumonitis and
GVHD by means of log-rank test models. Other
clinical related variables analyzed were the age, donor
type, recipient, and donor CMV serology, ABO
compatibility, stage of the disease, and use of a
radiation-based conditioning.To assess the association
of CMV genotypes with acute GVHD (aGVHD)
(grade II-IV) and chronic GVHD (cGVHD), a
similar methodology was used in a competing risk
Table 2. Proportional Hazards Regression Analysis of CMV
Pneumonitis
650 Biol Blood Marrow Transplant 16:647-652, 2010X. Wu et al.setting.All testswere 2 sided,with type I error rate fixed
at 0.05.Covariable P Value OR 95% CI
gB1 (n 5 36) — 1 —
gB2 (n 5 3) .2990 3.999 0.292-54.697
gB3 (n 5 39) .0058* 5.564 1.643-18.837
gB4 (n 5 1) ND ND ND
gB5 (n 5 5) .5755 1.999 0.177- 22.605
Mixed genotypes
(n 5 17)
.1091 3.332 0.764 -14.531
95% CI indicates 95% confidence interval; ND, not determined; OR,
odds ratio; CMV, cytomegalovirus.
*Significantly statistically different.RESULTS
CMV gB Genotype and Sequence
The distribution of CMV gB genotypes in HSCT
recipients were as following: gB1, 36 of 101 (35.64%);
gB2, 3 of 101 (2.97%); gB3, 39 of 101 (38.61%); and
gB4, 1 of 101 (0.99%). There were 17 patients
(16.83%) who had a combination of 2 different
CMV genotypes. There were 5 patients (4.95%) with
a CMV genotype that lacked an RsaI digestion site,
herein named gB5. Fifteen samples (3 with gB1, 3
with gB2, 3 with gB3, 1 with gB4, and 5 with gB5)
and all 17 mixed genotypes samples were sequenced.
The CMV sequences from the HSCT patients were
then compared to CMV sequences in GenBank. The
sequences of gB1 were 98% identical to GenBank
M60927. The sequences of gB2 were 99% identical
to GenBank M60931. Two sequences of gB3 were
98% identical to GenBank M60930.1 and 1 sequence
was 96% identical to GenBank AC146907.1. The
sequence of gB4 was 99% identical to GenBank
M60926. The sequences of gB5, which lacked an RsaI
site, were 99% identical to GenBank AC146906.1,
and this gB5 turned out to be a novel genotype of
CMV. All genotypes except gB3 were 95% homolo-
gous to each other, and gB3 was found to be the
most divergent 1 (Figure 2). Fifteen of 17 samples
among mixed genotypes sample had a combination of
gB1 and gB3, whereas 2 samples had a combination
of gB1 and gB2 following the cloning sequence.CMV gB Genotype and CMV Disease
Among these 101 patients, 67 had CMV viremia,
but they were asymptomatic. CMV disease manifested
as CMV pneumonitis (n5 23), CMV hepatitis (n5 4),
CMV gastrointestinal disease (n 53), CMV viral
syndrome (n 5 6), and myelosuppression (n 5 2).
CMV pneumonitis occurred in 13 of 39 (33.33%) pa-
tients with the gB3, in 5 of 36 (13.89%) patients with
the gB1, in 4 of 17 (23.52%) patients of mixed CMV
genotypes, and in 1 patient (of 5) with gB5. Of 17
mixed genotypes, 15 patients had a combination of
gB1 and gB3, and the others were gB1 and gB2.
With univariate analysis, the incidence of CMV
pneumonitis in patients with gB3 was statistically
significantly higher than that in patients with gB1
(P 5 .0454). With multivariate analysis, adjusted for
confounding variables, gB3 was associated with high
risk for CMV pneumonitis (Table 2), whereas there
were no significant differences among patients with
gB genotypes with respect to the other CMV disease
(P . .05).CMV gB Genotype and GVHD
Of 96 patients undergoing allogeneic transplanta-
tion, II-IV aGVHD occurred in 17 of 35 (48.57%) pa-
tients with the gB1, in 1 of 3 (33.3%) patients with the
gB2, in 12 of 37 (32.43%) patients of gB3, in 0 of 1
(0%) patients of gB4, in 2 of 5 (40%) patient with
gB5, and 8 of 15 (53.33%) patients of mixed CMV
genotypes. Extensive cGVHD occurred in 11 of
35(31.42%) patients with the gB1, in 2 of 3 (66.7%)
patients with the gB2, in 10 of 37 (27.03%) patients
of gB3, in 0 of 1 (0%) patients of gB4, in 2 of 5(40%)
patient with gB5, and 6 of 15 (40.00%) patients of
mixedCMVgenotypes.With univariate analysis, there
are no significant differences among patients with gB
genotypes with respect to the II-IV aGVHD (P .
.05). Among the patients who developed cGVHD, the
incidence of cGVHD was not statistically significant
among gB genotypes either (P . .05). By multivariate
analysis, donor type frommismatched related stem cells
was associated with high risk for aGVHD (P 5 .0083,
odds ratio [OR] 5 17.591, 95% confidence interval
[CI]: 2.093-147.86), whereas CMV genotypes were
not associated with aGVHD or cGVHD (Table 3).DISCUSSION
In this report, we confirmed that HCMV gB gen-
otyping could reliably identified 1 of 4 established gB
genotypes using 2 restriction endonucleases, HinfI
and RsaI, to digest the PCR-amplified variable region
of UL55 encoding the protease cleavage site
[12,20,21]. CMV gB1 and gB3 are the prevalent geno-
types inChineseHSCTpatients, whereas gB1 and gB2
were the major genotypes in other ethnic groups
[5,12,13,22]. To the best of our knowledge, this is
the first report on the large number of variants, partic-
ularly among gB3 strains in HSCT patients. Our data
also demonstrated that gB2 and gB4 were rare in
HSCT patients from China, which were not similar
with other studies from other counties [5,19]. In our
data, the percentage of mixed genotypes was 16.83%,
which was compatible with that of the percentage of
Table 3. Proportional Hazards Regression Analysis of GVHD
aGVHD cGVHD
Covariable P Value OR 95% CI P Value OR 95% CI
gB1 (n 5 35) — 1 — — 1 —
gB2 (n 5 3) .6467 0.559 0.046- 6.727 .7789 0.700 0.058 -8.445
gB3 (n 5 37) .1462 0.497 0.193- 1.276 .3274 0.622 0.241-1.608
gB4 (n 5 1) ND ND ND ND ND ND
gB5 (n 5 5) .7621 0.745 0.111-5.007 .9435 0.933 0.138-6.290
Mixed genotypes (n 5 15) .9911 0.993 0.313-3.155 .6583 0.764 0.231-2.523
95% CI indicates 95% confidence interval; ND, not determined; OR, odds ratio; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-
host disease.
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Unexpectedly we found 5 patients with a CMV variant
that lacked an RsaI site in the gB1 variant, and there-
fore did not belong to any of the 4 previous identified
genotypes; the subsequent sequencing data demon-
strated it was a novel variant, designated as gB5. This
novel variant was similar but not identical to another
rare genotype reported in 1998 from AIDS patients
[10], whose sequence was deposited into GenBank
named AC146906.1 in 2002 [24]. The gB5 variant
was 99% identical to GenBank AC146906.1, and was
first reported in this study to our knowledge.
In previous reports, the outcomes of different
CMV genotypes with clinical manifestations was con-
flicting. For example, CMV gB3 and gB4 were re-
ported to be associated with infectious complications
in HSCT patients [12], whereas Nogueira et al. [13]
reported that gB1 was associated with invasive disease
in solid organ transplantation. In our study, we ob-
served that CMV gB3 was associated with a higher in-
cidence of CMV pneumonitis, which was not reported
yet. In recent reports, mixed CMV genotypes were
observed to be associated with a higher prevalence of
CMV disease in solid organ transplant patients
[23,25]. All patients with mixed genotypes were not as-
sociated with CMV disease in our data. We hypothe-
sized the the reason was that the immunodeficiency
status in HSCT patients was more complicated than
that in solid organ transplant patients, and it was diffi-
cult to get meaningful results in such a limited number
of patients. The incidence of other CMV disease was
rare, and we could not observe an association of gB
genotypes with other CMV disease.
In addition to the direct effects of CMV infection,
CMV might also have an immunomodulatory effect.
Sarcinella et al. [23] reported that CMV infection
may be an important risk factor for the development
of graft rejection in solid organ transplantation.
Torok-Storb et al. [12] reported that CMV gB3 and
gB4 were associated with a reduced hazard of
GVHD in HSCT patients. In our study, we failed to
demonstrate an association of gB genotypes with
GVHD. The reason might be more than 1 factor
that could contribute to development of GVHD in
HSCT patients [26-28], and other virulence factorscould also help CMV evade the immune response
[29].
In summary, our findings suggest that CMV gB1
and gB3 are prevalent in HSCT patients and gB3
may be associatedwith higher incidence ofCMVpneu-
moitis in China. We also identified a novel CMV vari-
ant in a subset of Chinese HSCT patients. A larger
study needs to be performed to determine whether
the novel CMV variant had pathologic significance
among Chinese HSCT patients.ACKNOWLEDGMENTS
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